Dopaminergic binding sites in human pituitary adenomas other than prolactinomas.
Binding studies of [3H]-spiroperidol, a potent dopamine antagonist, were performed on dispersed cells obtained from 2 mixed PRL- and GH-secreting adenomas, 3 GH-secreting adenomas and 4 'nonsecreting' pituitary tumors. Saturable, high affinity binding sites for [3H]-spiroperidol were identified in the two adenomas of mixed PRL and GH secretion, in 2 of 3 GH-secreting adenomas and in 2 of 4 'nonsecreting' adenomas. These data indicate that dopaminergic binding sites are present in some GH-secreting adenomas in the absence of PRL hypersecretion and in some 'nonsecreting' pituitary adenomas.
D000236:Adenoma / Q000032:analysis* / Q000378:metabolism; D000328:Adult; D000368:Aged; D004298:Dopamine / Q000494:pharmacology; D005260:Female; D013006:Growth Hormone / Q000378:metabolism; D006801:Humans; D008297:Male; D008875:Middle Aged; D010911:Pituitary Neoplasms / Q000032:analysis* / Q000378:metabolism; D011388:Prolactin / Q000378:metabolism; D011954:Receptors, Dopamine / Q000032:analysis* / Q000378:metabolism; D013134:Spiperone / Q000378:metabolism
D011954:Receptors, Dopamine; D013134:Spiperone; D011388:Prolactin; D013006:Growth Hormone; D004298:Dopamine